Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative XELOX plus disitamab vedotin and PD-1 inhibitor for HER2-overexpressing locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2400081677Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin, capecitabine and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Pathological complete response. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
disitamab vedotincapecitabineoxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400081677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081677.